---
figid: PMC8835572__ijms-23-01155-g002
figtitle: Cancer as a Metabolic Disorder
organisms:
- NA
pmcid: PMC8835572
filename: ijms-23-01155-g002.jpg
figlink: /pmc/articles/PMC8835572/figure/ijms-23-01155-f002/
number: F2
caption: Mechanisms of glucose metabolic reprogramming in cancer. Hypoxia drives metabolic
  reprogramming in cancer cells. Increased expression of HIF transcription factors
  activates oncogenes (i.e., Ras, PI3K-Akt, and c-Myc) or inactivates tumor suppressors
  (p53 and PTEN) to sustain the glycolytic phenotype of cancer cells. Inactivation
  of the tumor suppressor gene TP53 is a common feature in cancers and contributes
  to the enhanced dependence on glycolysis. Inactivation of p53 releases repression
  of glucose transporters (e.g., GLUT1 and GLUT4) and decreases the expression of
  TIGAR, a glycolytic inhibitor. Activation of growth factor receptors activate the
  oncogenic PI3K/Akt pathway and activates downstream targets (FOXOs, HIF1a, c-Myc,
  and SREBP) that contribute to glucose metabolic reprogramming in cancer cells. Figure
  created using BioRender.
papertitle: Cancer as a Metabolic Disorder.
reftext: Jones Gyamfi, et al. Int J Mol Sci. 2022 Feb;23(3):1155.
year: '2022'
doi: 10.3390/ijms23031155
journal_title: International Journal of Molecular Sciences
journal_nlm_ta: Int J Mol Sci
publisher_name: MDPI
keywords: cancer | metabolism | glucose | glutamine | fatty acids
automl_pathway: 0.940347
figid_alias: PMC8835572__F2
figtype: Figure
organisms_ner:
- Drosophila melanogaster
- Homo sapiens
redirect_from: /figures/PMC8835572__F2
ndex: ''
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC8835572__ijms-23-01155-g002.html
  '@type': Dataset
  description: Mechanisms of glucose metabolic reprogramming in cancer. Hypoxia drives
    metabolic reprogramming in cancer cells. Increased expression of HIF transcription
    factors activates oncogenes (i.e., Ras, PI3K-Akt, and c-Myc) or inactivates tumor
    suppressors (p53 and PTEN) to sustain the glycolytic phenotype of cancer cells.
    Inactivation of the tumor suppressor gene TP53 is a common feature in cancers
    and contributes to the enhanced dependence on glycolysis. Inactivation of p53
    releases repression of glucose transporters (e.g., GLUT1 and GLUT4) and decreases
    the expression of TIGAR, a glycolytic inhibitor. Activation of growth factor receptors
    activate the oncogenic PI3K/Akt pathway and activates downstream targets (FOXOs,
    HIF1a, c-Myc, and SREBP) that contribute to glucose metabolic reprogramming in
    cancer cells. Figure created using BioRender.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - foxo
  - tgo
  - sima
  - Myc
  - SREBP
  - Akt
  - amon
  - Pten
  - Eaat1
  - Glut1
  - Glut4EF
  - Glut3
  - ras
  - Ras64B
  - Ras85D
  - G6P
  - p53
  - betaTub60D
  - hth
  - fbp
  - CycE
  - cyc
  - Kg
  - ATPsynbeta
  - Atpalpha
  - Pi3K21B
  - Pi3K59F
  - Pi3K68D
  - Pi3K92E
  - Dsor1
  - rl
  - FOXO1
  - FOXO3
  - FOXO4
  - FOXO6
  - HIF1A
  - SETD2
  - ARNT
  - MYC
  - ANGPT1
  - ANGPT2
  - ANGPT4
  - AREG
  - BDNF
  - CSF1
  - EFNA1
  - EFNA2
  - EFNA3
  - EFNA4
  - EFNA5
  - EGF
  - EREG
  - FGF1
  - FGF10
  - FGF16
  - FGF17
  - FGF18
  - FGF19
  - FGF2
  - FGF20
  - FGF21
  - FGF22
  - FGF23
  - FGF3
  - FGF4
  - FGF5
  - FGF6
  - FGF7
  - FGF8
  - FGF9
  - FLT3LG
  - HGF
  - IGF1
  - IGF2
  - INS
  - KITLG
  - NGF
  - NTF3
  - NTF4
  - PDGFA
  - PDGFB
  - PDGFC
  - PDGFD
  - PGF
  - TGFA
  - VEGFA
  - VEGFB
  - VEGFC
  - VEGFD
  - AKT1
  - AKT2
  - AKT3
  - EPAS1
  - HIF3A
  - ARNT2
  - BMAL1
  - PTEN
  - SLC2A1
  - KRAS
  - HRAS
  - NRAS
  - HK2
  - KCNA5
  - KIF2A
  - KLK2
  - HOOK2
  - TP53
  - TP63
  - TP73
  - FBP1
  - FOLR1
  - FOLR2
  - ECB2
  - FUBP1
  - RAB14
  - PKM
  - PKLR
  - LDHA
  - ATP8A2
  - PIK3CA
  - PIK3CB
  - PIK3CD
  - PIK3CG
  - PIK3R3
  - PIK3R4
  - PIK3R5
  - PIK3R6
  - PIK3R1
  - PIK3R2
  - MAP2K1
  - MAP2K2
  - MAPK3
  - MAPK1
---
